Shanghai Kingstar Winning Software (300253) fair value: what the stock is really worth
As of Sep 22, 2026: fair value of Shanghai Kingstar Winning Software ¥3.44, price ¥7.15, upside -51.9%, quality 47 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Shanghai Kingstar Winning Software for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range ¥5.14 – ¥18.10 · fair‑value band ¥2.04 – ¥5.40 · the ¥7.15 price screens above the ¥3.44 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Follow Shanghai Kingstar Winning Software in your weekly email
Every Wednesday you see whether Shanghai Kingstar Winning Software is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Winning Health Technology Group Co., Ltd., together with its subsidiaries, provides digital health services for medical and health institutions in China. The company offers WiNEX, a digital health platform; internet and health care; smart hospital; smart regional healthcare; and WinCloud solutions.
Show more
Winning Health Technology Group Co., Ltd., together with its subsidiaries, provides digital health services for medical and health institutions in China. The company offers WiNEX, a digital health platform; internet and health care; smart hospital; smart regional healthcare; and WinCloud solutions. Its solutions are used in smart hospitals, regional health, public health, medical insurance, health services, and other fields. The company is involved in general items; software development; information system operation and maintenance; investment; non-residential real estate leasing; technology development, transfer, and promotion; and medical device sale. In addition, it provides computer hardware, software, and peripherals; information technology consulting; internet data; technical consulting; and technical services. The company was formerly known as Shanghai Kingstar Winning Software Co., Ltd. and changed its name to Winning Health Technology Group Co., Ltd. in January 2016. Winning Health Technology Group Co., Ltd. was founded in 1994 and is headquartered in Shanghai, China.
Stock analysis
Shanghai Kingstar Winning Software (300253) currently trades at ¥7.15, while our model-based Fair Value estimate is ¥3.44, implying the stock looks roughly 107.9% overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ¥3.39 per share, and 0 of the 12 models we run sit above the ¥7.15 price.
Bear case: the Multiples group reads lowest at ¥1.38, and 12 of the 12 models stay below the price. Evidence for this calculation is medium.
Scenario range: ¥2.04 (bear) to ¥5.40 (bull), the price of ¥7.15 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Shanghai Kingstar Winning Software reported revenue of 2.1B CNY in FY2025 versus 2.8B CNY in FY2021, a compound −6.5%/yr. Reported net income was −374M CNY in FY2025.
Key figures
Market cap 15.8B CNY (≈ $2.4B) · P/S ratio 7.35 · EPS (TTM) ¥−0.1600 · Dividend yield 0.3% · Net margin −17.8% · Return on equity −6.6% · Return on assets (EBIT) 2.0% · Operating margin −0.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 51% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −52%, 300253 screens richer than that median.
Fair Value models
Bear ¥2.04Fair Value ¥3.44Bull ¥5.40
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.24/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−24.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−12.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.5%
Start year 2020 (pandemic). Over 10 years: +10.8% a year
Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
21.6% (2019) → −2.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+23.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+11.9%
Yearly sales growth analysts expect, extended to five years.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +21.7% a year for the price and +10.0% for the forecasts.
Compare Shanghai Kingstar Winning Software with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 135 stocks
Beats the industry median on 4/11 measures
Overall it trails its industry peers.
Valuation
Quality Score47 · Below median
Fair Value upside−52% · Below median
Profitability
Return on assets−2% · Below median
Net margin (TTM)−17% · Below median
Operating margin (TTM)0% · Below median
Growth and dividend
Revenue growth15% · Above median
Dividend yield (TTM)0.3% · Bottom 25%
Balance sheet
Debt / equity0.20× · Above median
Valuation Multiplesvs Health Information Services median · lower = cheaper
P/B0.42× · Cheapest 25%
P/S (TTM)1.10× · Cheaper than median
P/FCF7.1× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 6
FUTURE (revenue growth)76· sector 34
PAST (return on equity)0· sector 4
HEALTH (low debt)90· sector 98
DIVIDEND (yield)6· sector 46
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Shanghai Kingstar Winning Software (300253) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ¥3.44 versus a price of ¥7.15, about −52% upside (overvalued).
What is the fair value of 300253?
Our model-based fair value for Shanghai Kingstar Winning Software is ¥3.44 (as of Sep 24, 2026), built from audited fundamentals. The current price: ¥7.15.
What is the quality score of 300253?
Shanghai Kingstar Winning Software has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Shanghai Kingstar Winning Software (300253)?
Our model-based price target is the fair value of ¥3.44 (as of Sep 24, 2026) from 12 valuation models. Cautious scenario ¥2.04, optimistic scenario ¥5.40. It is a calculation from audited fundamentals, not an analyst target.
What is the Shanghai Kingstar Winning Software stock forecast for 2026?
Our models put fair value at ¥3.44, about −52% upside versus a price of ¥7.15 (overvalued). Cautious scenario ¥2.04, optimistic scenario ¥5.40. The calculation is refreshed regularly with new filings.
What is the revenue of Shanghai Kingstar Winning Software (300253)?
Shanghai Kingstar Winning Software reported trailing-twelve-month revenue of about 2.2B CNY (latest available figure, as of Sep 24, 2026).
Does Shanghai Kingstar Winning Software pay a dividend?
Shanghai Kingstar Winning Software currently shows a dividend yield of about 0.31% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Shanghai Kingstar Winning Software (300253)?
For today's price to be fair in a discounted-cash-flow model, Shanghai Kingstar Winning Software would have to grow free cash flow by +23.7 % per year for five years (discount rate 9.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -1.5 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 300253 use?
Our models discount Shanghai Kingstar Winning Software at 9.1 %: a base by market capitalisation (mid), damped by beta 0.46, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Shanghai Kingstar Winning Software that is +23.7 % per year a year over ten years, using the same discount rate (9.1 %) and the same formula as our fair value.
How much growth has Shanghai Kingstar Winning Software (300253) delivered so far?
Over the past 5 years revenue at Shanghai Kingstar Winning Software grew -1.5 % a year. The price currently implies +23.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Shanghai Kingstar Winning Software (300253) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Shanghai Kingstar Winning Software (+23.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Shanghai Kingstar Winning Software (300253)?
The free-cash-flow yield on the price is 2.11 %: that much free cash flow Shanghai Kingstar Winning Software produces per unit of market value. When it exceeds the discount rate of our models (9.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Shanghai Kingstar Winning Software (300253)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shanghai Kingstar Winning Software it is ¥3.44 per share (as of Sep 24, 2026), against a price of ¥7.15. It is the blended result of 12 valuation models (cash flow, earnings, asset, dividend).
Is Shanghai Kingstar Winning Software stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 300253 trades above its calculated fair value: price ¥7.15, fair value ¥3.44, a gap of about −52% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 300253?
No. The price is what the market pays today (¥7.15); the fair value is what the company's own numbers justify (¥3.44). For Shanghai Kingstar Winning Software the two are ¥3.71 per share apart. That gap is exactly why we show both numbers side by side.
How much is Shanghai Kingstar Winning Software worth?
The market values Shanghai Kingstar Winning Software at about 15.8B CNY (market capitalisation, as of Sep 24, 2026). Per share that is ¥7.15; our models calculate a fair value of ¥3.44 per share.
What do the bullish and bearish scenarios say about 300253?
Our models span a range for Shanghai Kingstar Winning Software: cautious scenario ¥2.04, base ¥3.44, optimistic ¥5.40 per share (as of Sep 24, 2026, price ¥7.15). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Shanghai Kingstar Winning Software (300253)?
Balance-sheet figures for Shanghai Kingstar Winning Software (as of Sep 24, 2026): return on equity −6.6%, debt of 0.20 per unit of equity. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is 300253 from its 52-week high?
Shanghai Kingstar Winning Software trades at ¥7.15, about 51% below its 52-week high of ¥14.73 and 10% above the low of ¥6.52 (as of Sep 22, 2026). Distance from the high says nothing about value: that is what the fair value of ¥3.44 is for.
Which stocks are comparable to Shanghai Kingstar Winning Software?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, HealthEquity, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Shanghai Kingstar Winning Software stock attractive at the current price?
The data as of Sep 24, 2026: price ¥7.15, calculated fair value ¥3.44 (−52%), Quality Score 47/100, from 12 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 300253 calculated?
We run Shanghai Kingstar Winning Software through 12 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥3.44, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Shanghai Kingstar Winning Software itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Shanghai Kingstar Winning Software (300253)?
The closing price on Sep 22, 2026 was ¥7.15. Our model-based fair value is ¥3.44, about −52% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Shanghai Kingstar Winning Software right now?
The price sits above even our optimistic bull case (¥5.40). The favourable scenario is already priced in. The model range is unusually wide (¥2.04 to ¥5.40). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (47/100) and above fair value, neither a clear bargain nor a standout compounder.
Where does the earnings growth of Shanghai Kingstar Winning Software (300253) come from?
Earnings per share at Shanghai Kingstar Winning Software grew +3.6 % a year from 2013 to 2024. Broken into its drivers: revenue per share +19.5 %, EBIT margin −11.3 %, tax rate −1.4 %, residual (interest, one-offs) −0.9 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Shanghai Kingstar Winning Software
How large is the market capitalisation of Shanghai Kingstar Winning Software (300253)?
The market capitalisation of Shanghai Kingstar Winning Software is 15.8B CNY (≈ $2.4B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Shanghai Kingstar Winning Software (300253)?
The price-to-sales ratio of Shanghai Kingstar Winning Software is 7.35 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Shanghai Kingstar Winning Software (300253)?
Earnings per share at Shanghai Kingstar Winning Software are ¥−0.1600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Shanghai Kingstar Winning Software (300253)?
The dividend yield of Shanghai Kingstar Winning Software is 0.3%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Shanghai Kingstar Winning Software (300253)?
The net margin of Shanghai Kingstar Winning Software is −17.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Shanghai Kingstar Winning Software (300253)?
The return on equity (ROE) of Shanghai Kingstar Winning Software is −6.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Shanghai Kingstar Winning Software (300253)?
On an EBIT basis the return on assets of Shanghai Kingstar Winning Software is 2.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Shanghai Kingstar Winning Software (300253)?
The operating margin of Shanghai Kingstar Winning Software is −0.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Shanghai Kingstar Winning Software (300253)?
Revenue at Shanghai Kingstar Winning Software is growing +15.2% versus a year earlier (3y avg −12.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Shanghai Kingstar Winning Software (300253)?
Earnings per share at Shanghai Kingstar Winning Software are growing +163% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Shanghai Kingstar Winning Software (300253) hold?
Shanghai Kingstar Winning Software holds more cash than debt, 230M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Shanghai Kingstar Winning Software in the live analysis
One click puts Shanghai Kingstar Winning Software on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
